相关实验视频
Updated: Jun 1, 2025

07:06
Pentylenetetrazole-Induced Kindling Mouse Model
Published on: June 12, 2018
32.8K
孟曼丁可以治疗自闭症吗? 来自临床前和临床研究的答案
Sawsan Aboul-Fotouh1, Sohir M Zohny1, Esraa M Elnahas1
1Clinical Pharmacology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
Neuroscience and biobehavioral reviews
|January 18, 2025
概括
孟坦丁是一种NMDA受体阻断剂,通过向神经炎症和失衡,显示出对自闭症谱系障碍 (ASD) 的临床前前景. 临床试验的结果不一,需要进一步的研究,以有效治疗ASD.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 发展障碍 发展障碍 发展障碍
背景情况:
- 自闭症谱系障碍 (ASD) 呈现出复杂的神经病理生理学和多样化的症状,使得有效的治疗成为优先事项.
- 目前针对ASD的治疗策略在准基本疾病机制方面面临挑战.
- 孟坦丁是一种NMDA受体对抗剂,正在研究其在ASD中的潜在治疗作用.
研究的目的:
- 审查孟坦因作为治疗自闭症谱系障碍的潜力.
- 在ASD的临床前模型中检查依据美曼丁作用的神经生物学机制.
- 评估当前临床证据,以评估孟坦丁在管理ASD核心症状和认知功能方面的疗效.
主要方法:
- 临床前研究 (动物模型) 和临床试验数据的叙述性综述.
- 对孟坦因对兴奋毒性,神经递质平衡 (GABA/谷氨酸),BDNF水平,血脑屏障完整性和神经炎症的影响的分析.
- 检查记忆素对社交互动,重复行为和ASD认知功能的影响.
主要成果:
- 临床前数据表明,孟坦因可以通过解决兴奋毒性,GABA/谷氨酸不平衡,减少BDNF,BBB泄漏和神经炎症来缓解与ASD相关的核心缺陷.
- 临床试验结果是矛盾的,一些研究表明症状严重程度和认知的适度改善,而另一些则显示有效性有限.
- 在ASD中记忆素的神经生物学机制仍然不完全理解.
结论:
- 孟曼丁在临床前模型中显示出改善ASD病理生理学的潜力.
- 梅曼丁对ASD的临床疗效尚未确定,需要进一步研究.
- 未来的研究应该集中于阐明机制和优化治疗策略在ASD管理中使用美曼丁.
相关概念视频
Alzheimer's Disease: Treatment
160
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
160
Alzheimer's Disease: Overview
439
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
439

